TuHURA BIOSCIENCES, INC./NV APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TuHURA BIOSCIENCES, INC./NV (HURA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $98.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2024-11-14
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $98.00K, a 38.75% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $156.00K, a 46.21% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-12-31 was $165.00K, a 62.16% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $160.00K, a 69.11% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $607.00K, a 59.26% decline from fiscal 2023.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.49M, a 34.73% decline from fiscal 2022.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.28M, a 56.73% decline from fiscal 2021.
- TuHURA BIOSCIENCES, INC./NV apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $5.28M, a 965.86% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | $98.00K 10-Q · filed 2024-11-14 | |||||
| 2024-06-30 | $607.00K 10-K · filed 2024-10-07 | |||||
| 2024-03-31 | $156.00K 10-Q · filed 2024-05-14 | $321.00K derived: sum of 2 quarters · filed 2024-05-14 | $481.00K derived: sum of 3 quarters · filed 2024-11-14 | |||
| 2023-12-31 | $165.00K 10-Q · filed 2024-05-14 | $325.00K derived: sum of 2 quarters · filed 2024-11-14 | ||||
| 2023-09-30 | $160.00K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $1.49M 10-K · filed 2024-10-07 | |||||
| 2023-03-31 | $290.00K 10-Q · filed 2024-05-14 | $726.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.24M derived: sum of 3 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $436.00K 10-Q · filed 2024-05-14 | $954.00K derived: sum of 2 quarters · filed 2024-05-14 | ||||
| 2022-09-30 | $518.00K 10-Q · filed 2024-05-14 | |||||
| 2022-06-30 | $2.28M 10-K · filed 2023-09-18 | $2.25M 10-K · filed 2022-09-27 | ||||
| 2022-03-31 | $642.00K 10-Q · filed 2023-05-11 | $1.47M derived: sum of 2 quarters · filed 2023-05-11 | $2.28M derived: sum of 3 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $830.00K 10-Q · filed 2023-05-11 | $1.64M derived: sum of 2 quarters · filed 2023-05-11 | ||||
| 2021-09-30 | $811.00K 10-Q · filed 2023-05-11 | |||||
| 2021-06-30 | $5.28M 10-K · filed 2022-09-27 | |||||
| 2021-03-31 | $1.72M 10-Q · filed 2022-05-13 | $3.84M derived: sum of 2 quarters · filed 2022-05-13 | $4.25M derived: sum of 3 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $2.13M 10-Q · filed 2022-05-13 | $2.53M derived: sum of 2 quarters · filed 2022-05-13 | ||||
| 2020-09-30 | $405.00K 10-Q · filed 2022-05-13 | |||||
| 2020-06-30 | $495.00K 10-K · filed 2021-09-28 | $494.86K 10-K · filed 2020-09-18 | ||||
| 2020-03-31 | $96.00K 10-Q · filed 2021-05-13 | $96.19K 10-Q · filed 2020-05-13 | $256.00K derived: sum of 2 quarters · filed 2021-05-13 | $307.00K derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $160.00K 10-Q · filed 2021-05-13 | $159.85K 10-Q · filed 2020-02-13 | $211.00K derived: sum of 2 quarters · filed 2021-05-13 | |||
| 2019-09-30 | $51.00K 10-Q · filed 2021-05-13 | $50.98K 10-Q · filed 2019-11-13 | ||||
| 2019-06-30 | $426.03K 10-K · filed 2020-09-18 | |||||
| 2019-03-31 | $99.73K 10-Q · filed 2020-05-13 | $222.49K derived: sum of 2 quarters · filed 2020-05-13 | $355.39K derived: sum of 3 quarters · filed 2020-05-13 | |||
| 2018-12-31 | $122.75K 10-Q · filed 2020-05-13 | $255.65K derived: sum of 2 quarters · filed 2020-05-13 | ||||
| 2018-09-30 | $132.90K 10-Q · filed 2020-05-13 | |||||
| 2018-06-30 | $495.93K 10-K · filed 2019-09-09 | |||||
| 2017-06-30 | $124.75K 8-K · filed 2019-06-03 | |||||
| 2016-06-30 | $251.69K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-27 | $394.13K 10-K · filed 2017-09-27 | $394.13K 10-K · filed 2016-09-13 | |||
| 2016-03-31 | $142.45K 10-Q · filed 2016-05-12 | |||||
| 2015-06-30 | $44.73K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13 | $108.48K derived: sum of 2 quarters · filed 2016-09-13 | $140.58K derived: sum of 3 quarters · filed 2016-09-13 | $187.18K 10-K · filed 2016-09-13 | ||
| 2015-03-31 | $63.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $95.85K derived: sum of 2 quarters · filed 2016-02-12 | $142.45K 10-Q · filed 2015-05-15 | $167.64K derived: sum of 4 quarters · filed 2016-02-12 | ||
| 2014-12-31 | $32.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | $78.69K 10-Q · filed 2016-02-12 | $103.89K derived: sum of 3 quarters · filed 2016-02-12 | $379.66K derived: sum of 4 quarters · filed 2016-02-12 | ||
| 2014-09-30 | $46.60K 10-Q · filed 2014-11-07 | $71.79K derived: sum of 2 quarters · filed 2015-11-16 | $347.56K derived: sum of 3 quarters · filed 2015-11-16 | $889.14K derived: sum of 4 quarters · filed 2015-11-16 | ||
| 2014-06-30 | $25.20K derived: 10-K 12 month − 10-Q 9 month · filed 2015-11-16 | $300.97K 10-K · filed 2014-08-28 | $842.55K derived: sum of 3 quarters · filed 2015-11-16 | $979.94K 10-K · filed 2015-11-16 | ||
| 2014-03-31 | $275.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15 | $817.35K derived: sum of 2 quarters · filed 2015-05-15 | $954.75K 10-Q · filed 2015-05-15 | $1.15M derived: sum of 4 quarters · filed 2015-05-15 | ||
| 2013-12-31 | $541.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-12 | $678.98K 10-Q · filed 2015-02-12 | $869.80K derived: sum of 3 quarters · filed 2015-02-12 | $890.65K 10-K · filed 2014-08-28 | ||
| 2013-09-30 | $137.40K 10-Q · filed 2014-11-07 | $328.22K derived: sum of 2 quarters · filed 2014-11-07 | $554.03K 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $190.83K derived: 10-K 6 month − 10-Q 3 month · filed 2014-08-28 | $211.67K 10-K · filed 2014-08-28 | ||||
| 2013-03-31 | $20.85K 10-Q · filed 2014-05-15 | |||||
| 2012-12-31 | $272.59K 10-K · filed 2014-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |